www.taro.com

Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.

News Release

 << Back



Taro Announces Completion of $250 Million Share Repurchase Program

PDF Version

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jan. 15, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it has completed its $250 million share repurchase program. The company bought back 2,493,378 of its ordinary shares in open market transactions at an average price of $100.28 per share. The repurchase program was announced by the company on November 23, 2016, and was completed on January 11, 2019.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

Source: Taro Pharmaceutical Industries Ltd.

Mariano A. Balaguer
VP, CFO
(914) 345-9001
Mariano.Balaguer@taro.com

William J. Coote
AVP, Business Finance, Treasurer and Investor Relations
(914) 345-9001
William.Coote@taro.com

Terms of Use		 |
Privacy Statement		 |
Safe Harbor Statement